Analysis and sorting of prostate cancer cell types by flow cytometry

Prostate

Volumn 40, Issue 3, 1999, Pages 192-199

  Liu, Alvin Y ^a   True, Lawrence D ^b   LaTray, Lean ^b   Ellis, William J ^a   Vessella, Robert L ^a   Lange, Paul H ^a   Higano, Celestia S ^b   Hood, Leroy ^b   Van Den Engh, Ger ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD44; CD57; Flow cytometry; Prostate cancer cells

Indexed keywords

CD57 ANTIGEN; HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL SORTER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ABDOMINAL NEOPLASMS; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, CD57; EPITHELIAL CELLS; FLOW CYTOMETRY; HUMANS; INTESTINAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0032783635     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990801)40:3<192::AID-PROS7>3.0.CO;2-F     Document Type: Article

References (25)

1. Cunha GR, Hayward SW, Dahiya R, Foster BA. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) 1996;55:63-72.
2. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
3. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, Morii S. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch [A] 1992;421:157-161.
4. Mostofi FK, Sesterhenn IA, Davis CJ. Prostatic carcinoma: problems in the interpretation of prostatic biopsies. Hum Pathol 1992;23:223-241.
5. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
6. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997;94:10705-10710.
7. Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS, Hood L. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 1997;30:145-153.
8. Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett 1994;76:63-69.
9. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmüller G, Pantel K. Phenorypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999; 59:241-248.
10. Liu X, Zhan B, Tomoyoshi T, Masanori T. Immunohistochemical study of HNK-1 (leu-7) antigen in prostate cancer and its clinical significance. Chin Med J [Engl] 1995;108:516-521.
11. Tanahashi T, Namba K, Murao T. Studies on relationship between histology, tumor markers and clinical course in prostate cancer. Nippon Hinyokika Gakkai Zasshi [Jpn J Urol] 1990;81: 680-685.
12. Mai KT, Commons S, Perkins DG, Yazdi HM, Collins JP. Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases. Hum Pathol 1996;27:1377-1381.
13. Rokhlin OW, Cohen MB. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 1995;26:205-212.
14. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997;33:263-271.
15. Zhang X, Sakamoto H, Takenaka I. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 1996;77:441-444.
16. Welsh CF, Zhu D, Bourguignon LYW. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-612.
17. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995;15:1191-1198.
18. Stevens JW, Palechek PL, Griebling TL, Midura RJ, Rokhlin OW, Cohen MB. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate 1996;28:153-161.
19. Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG, Kaufman R, Figge H, Ross JS. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Cancer 1996; 78:1461-1469.
20. Nagabhushan M, Pretlow TG, Guo Y, Amini SB, Pretlow TP, Sy M. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996;106:647-651.
21. Noordzij MA, van Steenbrugge G, Verkaik NS, Schröder FH, van der Kwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997;3:805-815.
22. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162-168.
23. Gao AC, Lou W, Dong J, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-849.
24. Takahashi S, Kimoto N, Orita S, Cui L, Sakakibara M, Shirai T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett 1998;129:97-102.
25. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-1048.